Real-time myoelectric control of knee and ankle motions for transfemoral amputees.

33.3% of candesartan patients received 76% or more of the target dose vs 78.0% of losartan patients. For the model using 150 mg of losartan as the target dose, 33.3% of candesartan patients received 25% or more of the target dose vs 0.2% of losartan patients. The actual mean (SD) dose of candesartan was 18 (11) mg (56% [36%] of the target dose of 32 mg) and of losartan, 53 (26) mg (106% [52%] of the target dose of 50 mg and 35% [17%] of the target dose of 150 mg). Candesartan was associated with less mortality than losartan in all models, with adjustment for dose with a target of 50 mg or 150 mg, and in multivariate models with and without propensity scores. There was no interaction with dose, regardless of whether the target losartan dose was 50 mg or 150 mg. This was a retrospective analysis and not a trial, but we agree that patients were likely titrated toward 50 mg prior to the HEAAL study and 150 mg after, if it was tolerated. Our findings should be confirmed in other studies, but the suggestion that candesartan is associated with lower mortality than losartan in HF remains.